ADT 030
Alternative Names: ADT-030Latest Information Update: 27 Jun 2025
At a glance
- Originator ADT Pharmaceuticals
- Class Antineoplastics; Indenes; Small molecules
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer
- No development reported Lung cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Lung-cancer in USA (PO)
- 31 May 2024 Pharmacodynamics and adverse events data from a preclinical studies in Pancreatic cancer presented at the60th Annual Meeting of the American Society of Clinical Oncology,2024 (ASCO-2024)